Diarrhea is a change in normal bowel movements characterized by increased frequency, water content or volume of stools.
Infectious diarrhea is diarrhea of infectious origin (bacteria, virus, protozoal) and is usually associated with symptoms of nausea and vomiting and abdominal cramps.
Dysentery (invasive diarrhea) has the presence of visible blood in diarrheic stool.
Repeat 2-week rifaximin treatment course (up to three) appears
to be effective and safe for patients with relapsing symptoms of
diarrhoea-predominant irritable bowel syndrome (IBS-D), producing marked
improvements in abdominal pain and frequency of loose stools without
increasing the incidence of adverse events, according to the results of a
phase III trial.
According to a systematic review and meta-analysis of 20 studies, the risk for Clostridium difficile-associated diarrhoea is elevated in patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD).
Lactobacillus rhamnosus L34 and Lactobacillus casei L39 are promising probiotics for the treatment of Clostridium difficile-associated diseases including hospital-acquired diarrhoea and colitis, based on a study.
Anal fissure is an ulceration of the anoderm in the anal canal. Treatments usually do not target these causative factors. Recently, this review has been published giving an update on the management of anal fissure.